5 Healthcare Stocks Soaring This Week
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 21 2025
0mins
Source: Benzinga
Top Performing Healthcare Stocks: Five healthcare stocks, including Sonoma Pharmaceuticals, Evoke Pharma, KALA Bio, Ginkgo Bioworks, and Soligenix, have shown significant week-on-week momentum gains, indicating potential breakout opportunities in the sector.
Sonoma Pharmaceuticals Highlights: Leading the pack, Sonoma Pharmaceuticals experienced a remarkable 66.73-point momentum score increase, driven by its focus on antimicrobial and dermatology products, with a 44.60% surge over the last month.
Evoke Pharma and KALA Bio Performance: Evoke Pharma's momentum score rose significantly due to its gastrointestinal treatment product, while KALA Bio saw a strong increase linked to therapies for rare ocular diseases, both showing impressive price trends.
Market Context and Momentum Ranking: The Benzinga Edge Rankings report highlights that these stocks' dramatic momentum gains reflect strong price performance and volatility, despite broader market declines in major ETFs like SPY and QQQ.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNA
Wall Street analysts forecast DNA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.280
Low
12.00
Averages
12.00
High
12.00
Current: 10.280
Low
12.00
Averages
12.00
High
12.00
About DNA
Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palantir vs. Ginkgo: The Biosecurity Debate
- Biosecurity Debate: Palantir and Ginkgo Bioworks stand on opposite sides of the emerging biosecurity debate, with Palantir focusing on intelligence and Ginkgo on biological infrastructure, highlighting the contention over whether future value lies in threat identification or rapid biological response.
- Market Performance Analysis: As of June 18, 2026, the stock performance of Palantir and Ginkgo has drawn investor attention, particularly as Palantir did not make the Motley Fool's list of top 10 stocks, indicating a lack of market appeal.
- Investment Recommendations: The analyst team has identified 10 stocks believed to potentially yield significant returns in the coming years, with Palantir's absence from this list suggesting investors should be cautious to avoid missing out on high-return opportunities.
- Historical Return Comparison: Historical examples like Netflix and Nvidia show that investing $1,000 at the time of their recommendations would have grown to $398,052 and $1,181,688 respectively, demonstrating the strong performance of Motley Fool's recommended stocks, while Palantir's exclusion may indicate insufficient growth potential ahead.
See More
Palantir and Ginkgo in Biosecurity Debate
- Biosecurity Debate: Palantir and Ginkgo Bioworks are positioned on opposite sides of a rapidly emerging biosecurity debate, with Palantir representing the intelligence layer and Ginkgo the biological infrastructure layer, highlighting their differing strategic directions in the future of biosecurity.
- Value Source Controversy: The core of the debate revolves around whether future value will stem from identifying threats first or building faster biological responses, a question that will significantly impact the competitive landscape for both companies in the biosecurity market.
- Market Reaction: As of June 18, 2026, Palantir's stock rose by 5.66% while Ginkgo's stock increased by 6.37%, reflecting a positive market perception of both companies' potential in the biosecurity sector.
- Strategic Implications: As biosecurity issues gain increasing attention, the debate between Palantir and Ginkgo not only affects their market positioning but may also guide the future development of biotechnology and security policies.
See More
Ginkgo Bioworks Launches ADME-One Platform for Drug Discovery
- Product Innovation: Ginkgo Bioworks, in collaboration with Tangible Scientific and Inductive Bio, has launched the ADME-One platform, which offers a high-throughput Tier 1 ADME panel combined with AI-driven human pharmacokinetic projections, significantly enhancing the efficiency and quality of drug discovery decisions.
- Cost Reduction: The introduction of ADME-One not only lowers the cost of an ADME panel but also transforms the timing of data utilization in the drug discovery process, enabling scientists to conduct comprehensive series characterization at earlier stages, thereby reducing surprises and synthesis waste later on.
- Integrated Workflow: The platform unites the best capabilities of three companies, providing standardized workflows that ensure data generation reliability and consistency, which accelerates the prioritization and validation of drug candidates.
- Market Response: In the context of U.S. and European drug developers responding to the BIOSECURE Act, ADME-One delivers a fully U.S.-based workflow that meets the growing demand for data sovereignty, which is expected to drive the company's market share in the biopharma industry.
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Ginkgo Bioworks Outlines FY26 Cash Burn Guidance Amid Stock Plunge
- Cash Burn Guidance: Ginkgo Bioworks projected a cash burn of $125M to $150M for FY26 during its Q1 earnings report, leading to a nearly 14% drop in stock price to $8.97 on Friday, indicating market concerns about its financial stability.
- Quarterly Performance: The company reported an EPS of -$1.28, slightly better than analysts' expectations, but revenue fell 50% year-over-year to $19M, primarily due to ongoing program rationalization and restructuring efforts, highlighting the challenges faced by the firm.
- Reduced Cash Burn: Cash burn for the first quarter was $48M, down 17% from $58M in the same quarter last year, which included a $14M payment to Google Cloud, reflecting the initial effectiveness of restructuring measures.
- Stock Price Fluctuations: Despite gaining 3.81% and 2.38% on Wednesday and Thursday respectively, Friday's decline erased previous gains, although the stock is up 7.22% year-to-date, moving in line with broader market trends.
See More
Palantir vs. Ginkgo: The Biosecurity Debate
- Biosecurity Debate: Palantir and Ginkgo Bioworks stand on opposite sides of the emerging biosecurity debate, with Palantir focusing on intelligence and Ginkgo on biological infrastructure, highlighting the contention over whether future value lies in threat identification or rapid biological response.
- Market Performance Analysis: As of June 18, 2026, the stock performance of Palantir and Ginkgo has drawn investor attention, particularly as Palantir did not make the Motley Fool's list of top 10 stocks, indicating a lack of market appeal.
- Investment Recommendations: The analyst team has identified 10 stocks believed to potentially yield significant returns in the coming years, with Palantir's absence from this list suggesting investors should be cautious to avoid missing out on high-return opportunities.
- Historical Return Comparison: Historical examples like Netflix and Nvidia show that investing $1,000 at the time of their recommendations would have grown to $398,052 and $1,181,688 respectively, demonstrating the strong performance of Motley Fool's recommended stocks, while Palantir's exclusion may indicate insufficient growth potential ahead.
See More
Palantir and Ginkgo in Biosecurity Debate
- Biosecurity Debate: Palantir and Ginkgo Bioworks are positioned on opposite sides of a rapidly emerging biosecurity debate, with Palantir representing the intelligence layer and Ginkgo the biological infrastructure layer, highlighting their differing strategic directions in the future of biosecurity.
- Value Source Controversy: The core of the debate revolves around whether future value will stem from identifying threats first or building faster biological responses, a question that will significantly impact the competitive landscape for both companies in the biosecurity market.
- Market Reaction: As of June 18, 2026, Palantir's stock rose by 5.66% while Ginkgo's stock increased by 6.37%, reflecting a positive market perception of both companies' potential in the biosecurity sector.
- Strategic Implications: As biosecurity issues gain increasing attention, the debate between Palantir and Ginkgo not only affects their market positioning but may also guide the future development of biotechnology and security policies.
See More
Ginkgo Bioworks Launches ADME-One Platform for Drug Discovery
- Product Innovation: Ginkgo Bioworks, in collaboration with Tangible Scientific and Inductive Bio, has launched the ADME-One platform, which offers a high-throughput Tier 1 ADME panel combined with AI-driven human pharmacokinetic projections, significantly enhancing the efficiency and quality of drug discovery decisions.
- Cost Reduction: The introduction of ADME-One not only lowers the cost of an ADME panel but also transforms the timing of data utilization in the drug discovery process, enabling scientists to conduct comprehensive series characterization at earlier stages, thereby reducing surprises and synthesis waste later on.
- Integrated Workflow: The platform unites the best capabilities of three companies, providing standardized workflows that ensure data generation reliability and consistency, which accelerates the prioritization and validation of drug candidates.
- Market Response: In the context of U.S. and European drug developers responding to the BIOSECURE Act, ADME-One delivers a fully U.S.-based workflow that meets the growing demand for data sovereignty, which is expected to drive the company's market share in the biopharma industry.
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Ginkgo Bioworks Outlines FY26 Cash Burn Guidance Amid Stock Plunge
- Cash Burn Guidance: Ginkgo Bioworks projected a cash burn of $125M to $150M for FY26 during its Q1 earnings report, leading to a nearly 14% drop in stock price to $8.97 on Friday, indicating market concerns about its financial stability.
- Quarterly Performance: The company reported an EPS of -$1.28, slightly better than analysts' expectations, but revenue fell 50% year-over-year to $19M, primarily due to ongoing program rationalization and restructuring efforts, highlighting the challenges faced by the firm.
- Reduced Cash Burn: Cash burn for the first quarter was $48M, down 17% from $58M in the same quarter last year, which included a $14M payment to Google Cloud, reflecting the initial effectiveness of restructuring measures.
- Stock Price Fluctuations: Despite gaining 3.81% and 2.38% on Wednesday and Thursday respectively, Friday's decline erased previous gains, although the stock is up 7.22% year-to-date, moving in line with broader market trends.
See More
